Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women.

Slides:



Advertisements
Similar presentations
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Advertisements

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D
Ambulatory Blood Pressure Monitoring in Clinical Practice: A Review
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial  Åsa Lindholm,
Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice  Lysanne.
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin.
Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome  Anuja Dokras, M.D., Ph.D., Shailly Saini,
The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study  Jeff G. Wang, M.D., Richard A. Anderson,
Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis  Héctor F. Escobar-Morreale, M.D., Ph.D., Manuel Luque-Ramírez,
Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women  Babak Mokhlesi, M.D.,
Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D
Michael M. Alper, M.D.  Fertility and Sterility 
Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters  Enrico Carmina, M.D., Francesco.
Michal Youngster, M. D. , Valerie L. Ward, M. D. , M. P. H. , Emily A
Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J
Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome  Anuja Dokras, M.D., Ph.D., Shailly Saini,
Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome  Sigrun B. Kjøtrød, M.D., Arne.
Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study  Cem Celik, M.D., Nicel.
Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome 
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome  Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,
Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study  Angela Kerchner, B.A., Whitney Lester,
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels 
Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.
Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F
Functional neuroimaging of emotional processing in women with polycystic ovary syndrome: a case-control pilot study  Courtney A. Marsh, M.D., M.P.H.,
Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome  Héctor F. Escobar-Morreale,
Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral.
Evolutionary determinants of polycystic ovary syndrome: part 1
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.
Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.
Clinical course of depression symptoms and predictors of enduring depression risk in women with polycystic ovary syndrome: Results of a longitudinal study 
Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens 
The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women.
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular.
Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced.
Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS)  F. Gonzalez,
Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity  Jean-Patrice Baillargeon, M.D.,
Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome  Macarena Alpañés, M.D., Manuel.
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Increased secretion of amylin in women with polycystic ovary syndrome
Prevalence of polycystic ovary syndrome in adolescents
Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S
Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a.
Antoni J. Duleba, M.D., Ibrahim M. Ahmed, M.D.  Fertility and Sterility 
Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized.
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment  Richard Fleming, Ph.D.,
Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D
Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial  Antoni J. Duleba, M.D.,
Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D
Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Manuel Maliqueo, Ph. D. , Bárbara Echiburú, Ph. D
Paolo Moghetti, M.D.  Fertility and Sterility 
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:
Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.
Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions  Kristen Farrell, M.S.,
Current evaluation of amenorrhea
Inappropriate gonadotropin secretion in polycystic ovary syndrome
Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome  Mesut Ozkaya, Assistant Professor, Erman Cakal, Specialist, Yusuf.
Effect of prior oophorectomy on changes in bone mineral density and carotid artery intima-media thickness in postmenopausal women  Sara J. Mucowski, M.D.,
Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients  Artemis Karkanaki,
Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test  Dimitrios Panidis, M.D., Ph.D., Dimitrios.
Increased risk of depressive disorders in women with polycystic ovary syndrome  Elizabeth Hollinrake, B.S., Alison Abreu, M.D., Michelle Maifeld, R.N.C.,
Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels 
Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity? 
Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular.
Presentation transcript:

Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome  Manuel Luque-Ramírez, M.D., Covadonga Mendieta-Azcona, M.D., Francisco Álvarez-Blasco, M.D., Héctor F. Escobar-Morreale, M.D., Ph.D.  Fertility and Sterility  Volume 91, Issue 6, Pages 2527-2536 (June 2009) DOI: 10.1016/j.fertnstert.2008.03.082 Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Changes in average daytime, nighttime, and 24-hour blood pressure and heart rate recordings of polycystic ovary syndrome patients treated with Diane35 Diario or metformin for 24 weeks. Data are mean ± standard error of the mean. Eleven patients completed the metformin arm (this arm had a large dropout rate, and the baseline ambulatory blood pressure monitoring recording was missing for one patient); the intention-to-treat analysis included all of the patients treated with metformin (n = 18). ∗P<.05 for the interaction between the arms of treatment, in both analysis of patients who completed the study and in intention-to-treat analysis. Fertility and Sterility 2009 91, 2527-2536DOI: (10.1016/j.fertnstert.2008.03.082) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Changes in the physiologic nocturnal decrease in systolic, diastolic, and mean blood pressure of polycystic ovary syndrome patients treated with Diane35 Diario or metformin for 24 weeks. Data are mean ± SEM. Eleven patients completed the metformin arm (this arm had a large dropout rate, and the baseline ambulatory blood pressure monitoring recording was missing for one patient); the intention-to-treat analysis included all of the patients treated with metformin (n = 18). Fertility and Sterility 2009 91, 2527-2536DOI: (10.1016/j.fertnstert.2008.03.082) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Changes in common carotid intima-media thickness of PCOS patients submitted to treatment with Diane35 Diario (n = 15) or metformin (n = 19) for 24 weeks in the whole of patients. Symbols and error bars are mean ± SEM. The shaded area represents the mean ± SEM of the nonhyperandrogenic control group. Because of the large drop-out rate in the metformin arm, the Figures show the analysis of the patients completing the study (n = 12) and an intention-to-treat analysis including all the patients treated with metformin (n = 19). ∗P<.05 compared with the control group of healthy women irrespective of the arm of treatment. Fertility and Sterility 2009 91, 2527-2536DOI: (10.1016/j.fertnstert.2008.03.082) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions